Abstract
Introduction: Managing ARDS is resource-intensive, but published quantitative data are limited.
Objective: To examine the healthcare resource utilization (HRU) and costs of patients hospitalized with ARDS.
Methods: US administrative claims between 2009 and 2013 of commercially-insured individuals and Medicare beneficiaries were analyzed. Patients with ARDS who received mechanical ventilation during the index hospitalization were selected. Each ARDS patient was demographically matched to 10 non-ARDS hospitalized controls. HRU, costs, and comorbidities during one-year prior (baseline), were compared, as were characteristics of the index hospitalization. One-year HRU and costs of a subgroup who were discharged alive and had at least one year follow-up were also examined.
Results: Commercially-insured hospitalized ARDS patients had greater comorbid conditions and prior hospitalizations than matched controls. During the index hospitalization, ARDS patients had longer stays (16.7 vs. 4.6 days), higher mortality (11.9% vs. 0.8%), and incurred higher costs than controls ($117,137 vs. $25,199; all p<0.05). ARDS patients who survived to discharge were more likely to be re-hospitalized (53.2% vs. 12.9%) and incurred higher annual total costs ($82,749 vs. $22,670; both p<0.05) during the subsequent year. Trends were similar for Medicare beneficiaries.
Conclusion: Patients hospitalized with ARDS incurred significantly higher resource utilization and costs than non-ARDS hospitalizations during and prior to the stay. The pattern persists for one year after hospital discharge.
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-2002
-
- There are more pages in this discussion • 15,816 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.10 |
Change
0.005(0.46%) |
Mkt cap ! $1.250B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.08 | $3.990M | 3.621M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
39 | 40609 | $1.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 44181 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
47 | 69423 | 1.090 |
18 | 125928 | 1.085 |
30 | 202254 | 1.080 |
10 | 83907 | 1.075 |
26 | 604339 | 1.070 |
Price($) | Vol. | No. |
---|---|---|
1.095 | 7442 | 2 |
1.100 | 83277 | 23 |
1.105 | 80583 | 11 |
1.110 | 33775 | 14 |
1.115 | 24030 | 7 |
Last trade - 14.05pm 10/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online